Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12379627rdf:typepubmed:Citationlld:pubmed
pubmed-article:12379627lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:12379627lifeskim:mentionsumls-concept:C0035435lld:lifeskim
pubmed-article:12379627lifeskim:mentionsumls-concept:C0666743lld:lifeskim
pubmed-article:12379627lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:12379627pubmed:dateCreated2002-10-15lld:pubmed
pubmed-article:12379627pubmed:abstractTextInfliximab is a chimeric anti-tumour necrosis factor alpha (TNFalpha) monoclonal antibody with high affinity and binding specificity for human TNFalpha. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves qualify of life. These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNFalpha has fast become an important therapeutic target in rheumatology.lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:languageenglld:pubmed
pubmed-article:12379627pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:citationSubsetIMlld:pubmed
pubmed-article:12379627pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12379627pubmed:statusMEDLINElld:pubmed
pubmed-article:12379627pubmed:monthNovlld:pubmed
pubmed-article:12379627pubmed:issn0003-4967lld:pubmed
pubmed-article:12379627pubmed:authorpubmed-author:St ClairE WEWlld:pubmed
pubmed-article:12379627pubmed:issnTypePrintlld:pubmed
pubmed-article:12379627pubmed:volume61 Suppl 2lld:pubmed
pubmed-article:12379627pubmed:ownerNLMlld:pubmed
pubmed-article:12379627pubmed:authorsCompleteYlld:pubmed
pubmed-article:12379627pubmed:paginationii67-9lld:pubmed
pubmed-article:12379627pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:meshHeadingpubmed-meshheading:12379627...lld:pubmed
pubmed-article:12379627pubmed:year2002lld:pubmed
pubmed-article:12379627pubmed:articleTitleInfliximab treatment for rheumatic disease: clinical and radiological efficacy.lld:pubmed
pubmed-article:12379627pubmed:affiliationDepartment of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC, USA. stcla003@mc.duke.edulld:pubmed
pubmed-article:12379627pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12379627pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12379627lld:pubmed